Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Cingulate Inc (CING)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wuxi Biologics (Cayman) (WXIBF – Research Report) and Cingulate Inc (CING – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuxi Biologics (Cayman) (WXIBF)
In a report released today, Laurence Tam from Morgan Stanley maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$35.00. The company’s shares closed last Tuesday at $3.85.
According to TipRanks.com, Tam is ranked #4613 out of 9989 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a $4.49 average price target, implying a 16.6% upside from current levels. In a report issued on August 8, UBS also upgraded the stock to Buy with a HK$41.20 price target.
See the top stocks recommended by analysts >>
Cingulate Inc (CING)
In a report released today, Naz Rahman from Maxim Group reiterated a Buy rating on Cingulate Inc, with a price target of $8.00. The company’s shares closed last Wednesday at $3.90, close to its 52-week low of $1.80.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cingulate Inc with a $24.75 average price target, a 544.5% upside from current levels. In a report issued on August 11, Roth MKM also reiterated a Buy rating on the stock with a $11.00 price target.
Read More on WXIBF:
